Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1796, Issue 2, 2009, Pages 230-241

  Peters, Jeffrey M ^a   Gonzalez, Frank J ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer; Cell proliferation; Differentiation; Peroxisome proliferator activated receptor

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; RETINOIC ACID;

APOPTOSIS; CANCER CELL CULTURE; CANCER MODEL; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; KERATINOCYTE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOMATIC CELL;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; KERATINOCYTES; NEOPLASMS; PPAR DELTA; PPAR-BETA; SKIN;

EID: 70349177505     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.06.002     Document Type: Review

References (119)

1. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4312-4317
2. Gupta R.A., Tan J., Krause W.F., Geraci M.W., Willson T.M., Dey S.K., and DuBois R.N. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13275-13280
3. Berger J., Leibowitz M.D., Doebber T.W., Elbrecht A., Zhang B., Zhou G., Biswas C., Cullinan C.A., Hayes N.S., Li Y., Tanen M., Ventre J., Wu M.S., Berger G.D., Mosley R., Marquis R., Santini C., Sahoo S.P., Tolman R.L., Smith R.G., and Moller D.E. Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects. J. Biol. Chem. 274 (1999) 6718-6725
4. Sznaidman M.L., Haffner C.D., Maloney P.R., Fivush A., Chao E., Goreham D., Sierra M.L., LeGrumelec C., Xu H.E., Montana V.G., Lambert M.H., Willson T.M., Oliver W.R., and Sternbach D.D. Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)-synthesis and biological activity. Bioorg. Med. Chem. Lett. 13 (2003) 1517-1521
5. Peters J.M., Hollingshead H.E., and Gonzalez F.J. Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin. Sci. (Lond). 115 (2008) 107-127
6. Kino T., Rice K.C., and Chrousos G.P. The PPARδ agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur. J. Clin. Invest. 37 (2007) 425-433
7. Woo C.H., Massett M.P., Shishido T., Itoh S., Ding B., McClain C., Che W., Vulapalli S.R., Yan C., and Abe J.I. ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor δ (PPARδ) stimulation. J. Biol. Chem. 281 (2006) 32164-32174
8. Shi Y., Hon M., and Evans R.M. The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2613-2618
9. Girroir E.E., Hollingshead H.E., He P., Zhu B., Perdew G.H., and Peters J.M. Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem. Biophys. Res. Commun. 371 (2008) 456-461
10. Leibowitz M.D., Fievet C., Hennuyer N., Peinado-Onsurbe J., Duez H., Bergera J., Cullinan C.A., Sparrow C.P., Baffic J., Berger G.D., Santini C., Marquis R.W., Tolman R.L., Smith R.G., Moller D.E., and Auwerx J. Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett. 473 (2000) 333-336
11. Oliver Jr. W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5306-5311
12. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., and Sakai J. Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15924-15929
13. Lee C.H., Olson P., Hevener A., Mehl I., Chong L.W., Olefsky J.M., Gonzalez F.J., Ham J., Kang H., Peters J.M., and Evans R.M. PPARδ regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3444-3449
14. Narkar V.A., Downes M., Yu R.T., Embler E., Wang Y.X., Banayo E., Mihaylova M.M., Nelson M.C., Zou Y., Juguilon H., Kang H., Shaw R.J., and Evans R.M. AMPK and PPARδ agonists are exercise mimetics. Cell 134 (2008) 405-415
15. Kilgore K.S., and Billin A.N. PPARβ/δ ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs 9 (2008) 463-469
16. Nagasawa T., Inada Y., Nakano S., Tamura T., Takahashi T., Maruyama K., Yamazaki Y., Kuroda J., and Shibata N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 536 (2006) 182-191
17. Qin X., Xie X., Fan Y., Tian J., Guan Y., Wang X., Zhu Y., and Wang N. Peroxisome proliferator-activated receptor-δ induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology 48 (2008) 432-441
18. Shan W., Nicol C.J., Ito S., Bility M.T., Kennett M.J., Ward J.M., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in mice. Hepatology 47 (2008) 225-235
19. Shan W., Palkar P.S., Murray I.A., McDevitt E.I., Kennett M.J., Kang B.H., Isom H.C., Perdew G.H., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol. Sci. 105 (2008) 418-428
20. Polak P.E., Kalinin S., Dello Russo C., Gavrilyuk V., Sharp A., Peters J.M., Richardson J., Willson T.M., Weinberg G., and Feinstein D.L. Protective effects of a peroxisome proliferator-activated receptor-β/δ agonist in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 168 (2005) 65-75
21. Michalik L., Desvergne B., Tan N.S., Basu-Modak S., Escher P., Rieusset J., Peters J.M., Kaya G., Gonzalez F.J., Zakany J., Metzger D., Chambon P., Duboule D., and Wahli W. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J. Cell. Biol. 154 (2001) 799-814
22. Peters J.M., Lee S.S.T., Li W., Ward J.M., Gavrilova O., Everett C., Reitman M.L., Hudson L.D., and Gonzalez F.J. Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor b(d). Mol. Cell. Biol. 20 (2000) 5119-5128
23. Man M.Q., Barish G.D., Schmuth M., Crumrine D., Barak Y., Chang S., Jiang Y., Evans R.M., Elias P.M., and Feingold K.R. Deficiency of PPARβ/δ in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J. Invest. Dermatol. 128 (2007) 370-377
24. Borland M.G., Foreman J.E., Girroir E.E., Zolfaghari R., Sharma A.K., Amin S.M., Gonzalez F.J., Ross A.C., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell proliferation in human HaCaT keratinocytes. Mol. Pharmacol. 74 (2008) 1429-1442
25. Burdick A.D., Bility M.T., Girroir E.E., Billin A.N., Willson T.M., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor-β/δ(PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes. Cell. Signal. 19 (2007) 1163-1171
26. Westergaard M., Henningsen J., Svendsen M.L., Johansen C., Jensen U.B., Schroder H.D., Kratchmarova I., Berge R.K., Iversen L., Bolund L., Kragballe K., and Kristiansen K. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J. Invest. Dermatol. 116 (2001) 702-712
27. Martinasso G., Maggiora M., Trombetta A., Canuto R.A., and Muzio G. Effects of di(2-ethylhexyl) phthalate, a widely used peroxisome proliferator and plasticizer, on cell growth in the human keratinocyte cell line NCTC 2544. J. Toxicol. Environ. Health, A. 69 (2006) 353-365
28. Kim D.J., Murray A., Burns A.M., Gonzalez F.J., Perdew G.H., and Peters J.M. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits epidermal cell proliferation by down-regulation of kinase activity. J. Biol. Chem. 280 (2005) 9519-9527
29. Kim D.J., Bility M.T., Billin A.N., Willson T.M., Gonzalez F.J., and Peters J.M. PPARβ/δ selectively induces differentiation and inhibits cell proliferation. Cell. Death Differ. 13 (2006) 53-60
30. Bility M.T., Devlin-Durante M.K., Blazanin N., Glick A.B., Ward J.M., Kang B.H., Kennett M.J., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits chemically-induced skin tumorigenesis. Carcinogenesis 29 (2008) 2406-2414
31. Kim D.J., Akiyama T.E., Harman F.S., Burns A.M., Shan W., Ward J.M., Kennett M.J., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor β (δ)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J. Biol. Chem. 279 (2004) 23719-23727
32. Schmuth M., Haqq C.M., Cairns W.J., Holder J.C., Dorsam S., Chang S., Lau P., Fowler A.J., Chuang G., Moser A.H., Brown B.E., Mao-Qiang M., Uchida Y., Schoonjans K., Auwerx J., Chambon P., Willson T.M., Elias P.M., and Feingold K.R. Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes. J. Invest. Dermatol. 122 (2004) 971-983
33. Romanowska M., al Yacoub N., Seidel H., Donandt S., Gerken H., Phillip S., Haritonova N., Artuc M., Schweiger S., Sterry W., and Foerster J. PPARδ enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J. Invest. Dermatol. 128 (2008) 110-124
34. Shearer B.G., and Hoekstra W.J. Recent advances in peroxisome proliferator-activated receptor science. Curr. Med. Chem. 10 (2003) 267-280
35. Matsuura H., Adachi H., Smart R.C., Xu X., Arata J., and Jetten A.M. Correlation between expression of peroxisome proliferator-activated receptor β and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol. Cell. Endocrinol. 147 (1999) 85-92
36. Tan N.S., Michalik L., Noy N., Yasmin R., Pacot C., Heim M., Fluhmann B., Desvergne B., and Wahli W. Critical roles of PPARβ/δ in keratinocyte response to inflammation. Genes Dev. 15 (2001) 3263-3277
37. Paramio J.M., Casanova M.L., Segrelles C., Mittnacht S., Lane E.B., and Jorcano J.L. Modulation of cell proliferation by cytokeratins K10 and K16. Mol. Cell. Biol. 19 (1999) 3086-3094
38. Lippens S., Kockx M., Knaapen M., Mortier L., Polakowska R., Verheyen A., Garmyn M., Zwijsen A., Formstecher P., Huylebroeck D., Vandenabeele P., and Declercq W. Epidermal differentiation does not involve the pro-apoptotic executioner caspases, but is associated with caspase-14 induction and processing. Cell. Death Differ. 7 (2000) 1218-1224
39. Weil M., Raff M.C., and Braga V.M. Caspase activation in the terminal differentiation of human epidermal keratinocytes. Curr. Biol. 9 (1999) 361-364
40. Gandarillas A., Goldsmith L.A., Gschmeissner S., Leigh I.M., and Watt F.M. Evidence that apoptosis and terminal differentiation of epidermal keratinocytes are distinct processes. Exp. Dermatol. 8 (1999) 71-79
41. Polakowska R.R., Piacentini M., Bartlett R., Goldsmith L.A., and Haake A.R. Apoptosis in human skin development: morphogenesis, periderm, and stem cells. Dev. Dyn. 199 (1994) 176-188
42. Di-Poi N., Tan N.S., Michalik L., Wahli W., and Desvergne B. Antiapoptotic role of PPARb in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell 10 (2002) 721-733
43. Schug T.T., Berry D.C., Shaw N.S., Travis S.N., and Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129 (2007) 723-733
44. Liang P., Jiang B., Huang X., Xiao W., Zhang P., Yang X., Long J., and Xiao X. Anti-apoptotic role of EGF in HaCaT keratinocytes via a PPARβ-dependent mechanism. Wound Repair Regen. 16 (2008) 691-698
45. Roop D.R., Huitfeldt H., Kilkenny A., and Yuspa S.H. Regulated expression of differentiation-associated keratins in cultured epidermal cells detected by monospecific antibodies to unique peptides of mouse epidermal keratins. Differentiation 35 (1987) 143-150
46. Tyner A.L., and Fuchs E. Evidence for posttranscriptional regulation of the keratins expressed during hyperproliferation and malignant transformation in human epidermis. J. Cell. Biol. 103 (1986) 1945-1955
47. Schug T.T., Berry D.C., Toshkov I.A., Cheng L., Nikitin A.Y., and Noy N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 7546-7551
48. Rieck M., Meissner W., Ries S., Muller-Brusselbach S., and Muller R. Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) β/δ: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Mol. Pharmacol. 74 (2008) 1269-1277
49. Chen W.C., Sass J.O., Seltmann H., Nau H., Orfanos C.E., and Zouboulis C.C. Biological effects and metabolism of 9-cis-retinoic acid and its metabolite 9,13-di-cis-retinoic acid in HaCaT keratinocytes in vitro: comparison with all-trans-retinoic acid. Arch. Dermatol. Res. 292 (2000) 612-620
50. Hansen L.A., Sigman C.C., Andreola F., Ross S.A., Kelloff G.J., and De Luca L.M. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21 (2000) 1271-1279
51. Kanekura T., Higashi Y., and Kanzaki T. Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase (COX)-2 expression and cell growth in human skin squamous carcinoma cells. Cancer Lett. 161 (2000) 177-183
52. Klaassen I., Brakenhoff R.H., Smeets S.J., Snow G.B., and Braakhuis B.J. Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells. Br. J. Cancer 85 (2001) 630-635
53. Memezawa A., Takada I., Takeyama K., Igarashi M., Ito S., Aiba S., Kato S., and Kouzmenko A.P. Id2 gene-targeted crosstalk between Wnt and retinoid signaling regulates proliferation in human keratinocytes. Oncogene 26 (2007) 5038-5045
54. Tong P.S., Mayes D.M., and Wheeler L.A. Differential effects of retinoids on DNA synthesis in calcium-regulated murine epidermal keratinocyte cultures. J. Invest. Dermatol. 90 (1988) 861-868
55. Chen L.C., Kirchhoff S., and De Luca L.M. Effect of excess dietary retinoic acid on skin papilloma and carcinoma formation induced by a complete carcinogenesis protocol in female Sencar mice. Cancer Lett. 78 (1994) 63-67
56. Chen L.C., Sly L., and De Luca L.M. High dietary retinoic acid prevents malignant conversion of skin papillomas induced by a two-stage carcinogenesis protocol in female SENCAR mice. Carcinogenesis 15 (1994) 2383-2386
57. Tennenbaum T., Lowry D., Darwiche N., Morgan D.L., Gartsbein M., Hansen L., De Luca L.M., Hennings H., and Yuspa S.H. Topical retinoic acid reduces skin papilloma formation but resistant papillomas are at high risk for malignant conversion. Cancer Res. 58 (1998) 1435-1443
58. Verma A.K. Inhibition of both stage I and stage II mouse skin tumour promotion by retinoic acid and the dependence of inhibition of tumor promotion on the duration of retinoic acid treatment. Cancer Res. 47 (1987) 5097-5101
59. Verma A.K. Inhibition of tumor promoter 12-O-tetradecanoylphorbol-13-acetate-induced synthesis of epidermal ornithine decarboxylase messenger RNA and diacylglycerol-promoted mouse skin tumor formation by retinoic acid. Cancer Res. 48 (1988) 2168-2173
60. Verma A.K., Slaga T.J., Wertz P.W., Mueller G.C., and Boutwell R.K. Inhibition of skin tumor promotion by retinoic acid and its metabolite 5,6-epoxyretinoic acid. Cancer Res. 40 (1980) 2367-2371
61. Xu H., Cheepala S., McCauley E., Coombes K., Xiao L., Fischer S.M., and Clifford J.L. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression. Clin. Cancer Res. 12 (2006) 969-979
62. Shirotani M., Yui Y., Hattori R., and Kawai C. U-61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins 41 (1991) 97-110
63. Müller-Brüsselbach S., Kömhoff M., Rieck M., Meissner W., Kaddatz K., Adamkiewicz J., Keil B., Klose K.J., Moll R., Burdick A.D., Peters J.M., and Müller R. Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient mice. EMBO J. 26 (2007) 3686-3698
64. Liou J.Y., Lee S., Ghelani D., Matijevic-Aleksic N., and Wu K.K. Protection of endothelial survival by peroxisome proliferator-activated receptor-δ mediated 14-3-3 upregulation. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1481-1487
65. Piqueras L., Reynolds A.R., Hodivala-Dilke K.M., Alfranca A., Redondo J.M., Hatae T., Tanabe T., Warner T.D., and Bishop-Bailey D. Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 63-69
66. Stephen R.L., Gustafsson M.C., Jarvis M., Tatoud R., Marshall B.R., Knight D., Ehrenborg E., Harris A.L., Wolf C.R., and Palmer C.N. Activation of peroxisome proliferator-activated receptor δ stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res. 64 (2004) 3162-3170
67. Han J.K., Lee H.S., Yang H.M., Hur J., Jun S.I., Kim J.Y., Cho C.H., Koh G.Y., Peters J.M., Park K.W., Cho H.J., Lee H.Y., Kang H.J., Oh B.H., Park Y.B., and Kim H.S. Peroxisome proliferator-activated receptor-δ agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation 118 (2008) 1021-1033
68. 2 stress protects human umbilical vein endothelial cells from subsequent oxidative stress-induced apoptosis. Free Radic. Biol. Med. 46 (2009) 555-563
69. Clapp L.H., Finney P., Turcato S., Tran S., Rubin L.J., and Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell. Mol. Biol. 26 (2002) 194-201
70. Hara S., Morishita R., Tone Y., Yokoyama C., Inoue H., Kaneda Y., Ogihara T., and Tanabe T. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 216 (1995) 862-867
71. Li R.C., Cindrova-Davies T., Skepper J.N., and Sellers L.A. Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor. Circ. Res. 94 (2004) 759-767
72. Lim H.J., Lee S., Park J.H., Lee K.S., Choi H.E., Chung K.S., Lee H.H., and Park H.Y. PPARδ agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis 202 (2009) 446-454
73. Lin H., Lee J.L., Hou H.H., Chung C.P., Hsu S.P., and Juan S.H. Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J. Cell. Physiol. 214 (2008) 434-441
74. Hellemans K., Michalik L., Dittie A., Knorr A., Rombouts K., De Jong J., Heirman C., Quartier E., Schuit F., Wahli W., and Geerts A. Peroxisome proliferator-activated receptor-β signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124 (2003) 184-201
75. Ali F.Y., Egan K., Fitzgerald G.A., Desvergne B., Wahli W., Bishop-Bailey D., Warner T.D., and Mitchell J.A. Role of prostacyclin receptor versus PPARβ with treprostinil sodium on lung fibroblast proliferation. Am. J. Respir. Cell. Mol. Biol. 34 (2005) 242-246
76. Zhang H., Pi R., Li R., Wang P., Tang F., Zhou S., Gao J., Jiang J., Chen S., and Liu P. PPARβ/δ activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts. Arch. Biochem. Biophys. 460 (2007) 25-32
77. Teunissen B.E., Smeets P.J., Willemsen P.H., De Windt L.J., Van der Vusse G.J., and Van Bilsen M. Activation of PPARδ inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovasc. Res. 75 (2007) 519-529
78. Zeng L., Geng Y., Tretiakova M., Yu X., Sicinski P., and Kroll T.G. Peroxisome proliferator-activated receptor-δ induces cell proliferation by a cyclin E1-dependent mechanism and is up-regulated in thyroid tumors. Cancer Res. 68 (2008) 6578-6586
79. Letavernier E., Perez J., Joye E., Bellocq A., Fouqueray B., Haymann J.P., Heudes D., Wahli W., Desvergne B., and Baud L. Peroxisome proliferator-activated receptor β/δ exerts a strong protection from ischemic acute renal failure. J. Am. Soc. Nephrol. 16 (2005) 2395-2402
80. Pesant M., Sueur S., Dutartre P., Tallandier M., Grimaldi P.A., Rochette L., and Connat J.L. Peroxisome proliferator-activated receptor δ (PPARδ) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc. Res. 69 (2006) 440-449
81. Hatae T., Wada M., Yokoyama C., Shimonishi M., and Tanabe T. Prostacyclin-dependent apoptosis mediated by PPARδ. J. Biol. Chem. 276 (2001) 46260-46267
82. J. Clark, R. Nasrallah, R.L. Hebert, The PPARδ ligand GW501516 reduces growth but not apoptosis in mouse inner medullary collecting duct cells, PPAR research 2009 (2009) 706283.
83. He T.C., Chan T.A., Vogelstein B., and Kinzler K.W. PPARd is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99 (1999) 335-345
84. Gupta R.A., Wang D., Katkuri S., Wang H., Dey S.K., and DuBois R.N. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat. Med. 10 (2004) 245-247
85. Wang D., Wang H., Guo Y., Ning W., Katkuri S., Wahli W., Desvergne B., Dey S.K., and Dubois R.N. Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 19069-19074
86. Wang D., Wang H., Shi Q., Katkuri S., Walhi W., Desvergne B., Das S.K., Dey S.K., and DuBois R.N. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell. 6 (2004) 285-295
87. J.E. Foreman, J.M. Sorg, K.S. McGinnis, B. Rigas, J.L. Williams, M.L. Clapper, F.J. Gonzales, J.M. Peters, Regulation of peroxisome proliferator-activated receptor-β/δ by the APC/β-CATENIN pathway and nonsteroidal anti-inflammatory drugs, Molecular Carcinogenesis doi:10.1002/mc.20546 (2009).
88. Hollingshead H.E., Killins R.L., Borland M.G., Girroir E.E., Billin A.N., Willson T.M., Sharma A.K., Amin S., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 28 (2007) 2641-2649
89. Marin H.E., Peraza M.A., Billin A.N., Willson T.M., Ward J.M., Kennett M.J., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) inhibits colon carcinogenesis. Cancer Res. 66 (2006) 4394-4401
90. Yang L., Zhou Z.G., Zheng X.L., Wang L., Yu Y.Y., Zhou B., Gu J., and Li Y. RNA Interference against peroxisome proliferator-activated receptor δ gene promotes proliferation of human colorectal cancer cells. Dis. Colon Rectum 51 (2008) 318-328
91. Harman F.S., Nicol C.J., Marin H.E., Ward J.M., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat. Med. 10 (2004) 481-483
92. Hollingshead H.E., Borland M.G., Billin A.N., Willson T.M., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 29 (2008) 169-176
93. Kohno H., Suzuki R., Sugie S., and Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 5 (2005) 46
94. Tenenbaum A., Boyko V., Fisman E.Z., Goldenberg I., Adler Y., Feinberg M.S., Motro M., Tanne D., Shemesh J., Schwammenthal E., and Behar S. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?. Cardiovasc. Diabetol. 7 (2008) 18
95. Yin Y., Russell R.G., Dettin L.E., Bai R., Wei Z.L., Kozikowski A.P., Kopleovich L., and Glazer R.I. Peroxisome proliferator-activated receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 65 (2005) 3950-3957
96. Girroir E.E., Hollingshead H.E., Billin A.N., Willson T.M., Robertson G.P., Sharma A.K., Amin S., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology 243 (2008) 236-243
97. Fukumoto K., Yano Y., Virgona N., Hagiwara H., Sato H., Senba H., Suzuki K., Asano R., Yamada K., and Yano T. Peroxisome proliferator-activated receptor δ as a molecular target to regulate lung cancer cell growth. FEBS Lett. 579 (2005) 3829-3836
98. Muller-Brusselbach S., Ebrahimsade S., Jakel J., Eckhardt J., Rapp U.R., Peters J.M., Moll R., and Muller R. Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARβ/δ gene. Int. J. Oncol. 31 (2007) 607-611
99. Keith R.L., Miller Y.E., Hoshikawa Y., Moore M.D., Gesell T.L., Gao B., Malkinson A.M., Golpon H.A., Nemenoff R.A., and Geraci M.W. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res. 62 (2002) 734-740
100. Keith R.L., Miller Y.E., Hudish T.M., Girod C.E., Sotto-Santiago S., Franklin W.A., Nemenoff R.A., March T.H., Nana-Sinkam S.P., and Geraci M.W. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res. 64 (2004) 5897-5904
101. Han S., Ritzenthaler J.D., Wingerd B., and Roman J. Activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein β. J. Biol. Chem. 280 (2005) 33240-33249
102. Han S., Ritzenthaler J.D., Zheng Y., and Roman J. PPARβ/δ agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. Am. J. Physiol. Lung Cell. Mol. Physiol. 294 (2008) L1238-1249
103. Pedchenko T.V., Gonzalez A.L., Wang D., DuBois R.N., and Massion P.P. Peroxisome proliferator-activated receptor β/δ expression and activation in lung cancer. Am. J. Respir. Cell. Mol. Biol. 39 (2008) 689-696
104. He P., Borland M.G., Zhu B., Sharma A.K., Amin S., El-Bayoumy K., Gonzalez F.J., and Peters J.M. Effect of ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in human lung cancer cell lines. Toxicology 254 (2008) 112-117
105. Glinghammar B., Skogsberg J., Hamsten A., and Ehrenborg E. PPARδ activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 308 (2003) 361-368
106. Xu L., Han C., Lim K., and Wu T. Cross-talk between peroxisome proliferator-activated receptor δ and cytosolic phospholipase A2α/cyclooxygenase-2/prostaglandin E2 signaling pathways in human hepatocellular carcinoma cells. Cancer Res. 66 (2006) 11859-11868
107. Xu L., Han C., and Wu T. A novel positive feedback loop between PPARδ and PGE2 signaling pathways for human cholangiocarcinoma cell growth. J. Biol. Chem. 281 (2006) 33982-33996
108. Berge K., Tronstad K.J., Flindt E.N., Rasmussen T.H., Madsen L., Kristiansen K., and Berge R.K. Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 22 (2001) 1747-1755
109. Otsuyama K.I., Ma Z., Abroun S., Amin J., Shamsasenjan K., Asaoku H., and Kawano M.M. PPARβ-mediated growth suppression of baicalein and dexamethasone in human myeloma cells. Leukemia 21 (2007) 187-190
110. Di Loreto S., D'Angelo B., D'Amico M.A., Benedetti E., Cristiano L., Cinque B., Cifone M.G., Ceru M.P., Festuccia C., and Cimini A. PPARβ agonists trigger neuronal differentiation in the human neuroblastoma cell line SH-SY5Y. J. Cell. Physiol. 211 (2007) 837-847
111. Ou Y.C., Yang C.R., Cheng C.L., Raung S.L., Hung Y.Y., and Chen C.J. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur. J. Pharmacol. 563 (2007) 49-60
112. Delage B., Rullier A., Capdepont M., Rullier E., and Cassand P. The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr. J. 6 (2007) 20
113. Feilchenfeldt J., Brundler M.A., Soravia C., Totsch M., and Meier C.A. Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARγ-coactivator 1 (PGC-1). Cancer Lett. 203 (2004) 25-33
114. Knutsen H.K., Olstorn H.B., Paulsen J.E., Husoy T., Goverud I.L., Loberg E.M., Kristiansen K., and Alexander J. Increased levels of PPARβ/δ and cyclin D1 in flat dysplastic ACF and adenomas in Apc(Min/+) mice. Anticancer Res. 25 (2005) 3781-3789
115. Ouyang N., Williams J.L., and Rigas B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)δ expression in APC(min/+) mice proportionally to their tumor inhibitory effect: implications for the role of PPARδ in carcinogenesis. Carcinogenesis 27 (2006) 232-239
116. Takayama O., Yamamoto H., Damdinsuren B., Sugita Y., Ngan C.Y., Xu X., Tsujino T., Takemasa I., Ikeda M., Sekimoto M., Matsuura N., and Monden M. Expression of PPARδ in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br. J. Cancer 95 (2006) 889-895
117. Liou J.Y., Ghelani D., Yeh S., and Wu K.K. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res. 67 (2007) 3185-3191
118. Shureiqi I., Jiang W., Zuo X., Wu Y., Stimmel J.B., Leesnitzer L.M., Morris J.S., Fan H.Z., Fischer S.M., and Lippman S.M. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9968-9973
119. Tuder R.M., and Zaiman A.L. Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: is it sufficient to treat severe pulmonary hypertension?. Am. J. Respir. Cell. Mol. Biol. 26 (2002) 171-174